Table 7 On-treatment adverse events reported by ≥3% of patients within any treatment group (mITT population)
Number (%) of patients | |||||
|---|---|---|---|---|---|
Preferred term | UMEC QD | ||||
Placebo | 15.6 μg | 31.25 μg | 62.5 μg | 125 μg | |
N = 60 | N = 60 | N = 57 | N = 59 | N = 60 | |
Headache | 2 (3) | 1 (2) | 0 | 0 | 3 (5) |
Nasopharyngitis | 0 | 1 (2) | 0 | 0 | 1 (2) |
Dysgeusia | 0 | 1 (2) | 0 | 0 | 2 (3) |
Sinusitis | 0 | 0 | 0 | 0 | 2 (3) |
Preferred term | UMEC BID | Tiotropium | |||
15.6 μg | 31.25 μg | QD 18 μg | |||
N = 56 | N = 58 | N = 56 | |||
Headache | 4 (7) | 1 (2) | 0 | ||
Nasopharyngitis | 0 | 0 | 2 (4) | ||
Dysgeusia | 0 | 0 | 0 | ||
Sinusitis | 0 | 0 | 0 | ||